Detalhe da pesquisa
1.
Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study.
Leuk Lymphoma
; 61(13): 3112-3119, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32844699
2.
Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety.
Leuk Lymphoma
; 55(12): 2813-6, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24724785
3.
Descripción de las caracteristicas clínicas de las neoplasias mieloproliferativas crónicas (NMPC). Primer informe del registro colombiano de NMPC / Description of the clinical characteristics of chronic myeloproliferative neoplasms (MPNs). First report of the colombian registry of MPNs
Acta méd. colomb
; 42(1): 35-41, ene.-mar. 2017. tab, graf
Artigo
em Espanhol
| LILACS, COLNAL | ID: biblio-886337
4.
Tratamiento con imatinib y el farmacogenotipo CYP3A4 en relación con la expansión clonal Ph(+) en leucemia mieloide crónica (LMC) / Imatinib treatment and pharmacogenotype CYP3A4 in relation with the clonal expansion Ph(+) in chronic myeloid leukemia (CML)
Colomb. med
; 39(4): 314-322, oct.-dic. 2008. ilus, tab
Artigo
em Espanhol
| LILACS | ID: lil-573374
5.
Protesis parcial de cadera en una hemofilia clasica severa. / Partial hip prothesis in acute classic hemophilia
Acta méd. colomb
; 9(1): 28-33, 1984.
Artigo
em Espanhol
| LILACS | ID: lil-26287